About a month after receiving the booster shot, study participants who got the omicron subvariant BA.4/BA.5-focused vaccine had “similar neutralizing antibody titers as those receiving a fourth monovalent mRNA vaccine.” All variants and subvariants were tested.
The study evaluated Pfizer’s and Moderna’s tweaked boosters, which were authorized Sept. 1. In recent weeks, the vaccine-makers have reported positive results showing their shots are safe and effective.
The researchers, who are from New York’s Columbia University and Ann Arbor’s University of Michigan, concluded that follow-up studies are needed to determine whether “antibody responses will deviate in time, including the impact of a second bivalent booster.”
More bivalent boosters could be on the horizon. Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci, MD, said in early September that COVID-19 vaccine jabs could become as regular as flu shots — but that could mean a universal vaccine, which is still in development, or a new modified vaccine every year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
